Results 181 to 190 of about 29,392 (272)

Real-world management of tuberous sclerosis complex-associated renal angiomyolipomas: the impact of mTOR inhibitors. [PDF]

Clin Kidney J
Gemander N, Dao M, Kalbacher E, Fantoni JC, Provot F, Correas JM, Joly D.   +6 more
europepmc   +1 more source

Theranostic Advancements in Brain Cancer: Promising Approaches for Emerging Therapy

MedComm – Oncology, Volume 5, Issue 2, June 2026.
Strategies for improving intra‐arterial administration (A) and photodynamic therapy in brain cancer (B). Improving intra‐arterial (IA) administration and photodynamic therapy (PDT) for brain cancer involves enhancing tumor targeting and breaching the blood–brain barrier (BBB). Key strategies include super selective catheterization, using osmotic agents
Bipraban Khanra, Manoj Kumar Sarangi
wiley   +1 more source

Advantages of optical coherence tomography in assessing retinal astrocytic hamartomas in children with tuberous sclerosis complex. [PDF]

Front Med (Lausanne)
Dou G, Zhou Z, Sun J, Zhang Z, Wang C, Sun D, Zhu J, Zhu Y, Zhang H, Wang Q, Li M, Deng Y, Wang Y.   +12 more
europepmc   +1 more source

Exploring the use of smartphone monitoring for young adults with Tuberous Sclerosis Complex (TSC): a qualitative analysis. [PDF]

Orphanet J Rare Dis
Fifield K, Blackford K, Snaith B, Singhania A, Tye C, Simblett S.   +5 more
europepmc   +1 more source

The pathophysiology of tuberous sclerosis complex [PDF]

Epilepsia, 2010
openaire   +2 more sources

Correction: Gut microbiota signatures in tuberous sclerosis complex and epilepsy: a pilot study. [PDF]

Front Neurosci
Ottaviano E, Marsiglia MD, Ceccarani C, Ancona S, Triva F, La Briola F, Bergamoni S, Teutonico F, Pompili A, Viganò I, Ricci E, Vignoli A, Borghi E.   +12 more
europepmc   +1 more source

Virtual Screening and Zebrafish Phenotype‐Based Evaluation Argues Against Repurposing 4‐Phenylbutyrate for STXBP1‐Related Disorders

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT Syntaxin‐binding protein 1 (STXBP1) mutations lead to severe epilepsy, intellectual disability, developmental delay, and movement disorder. Effective treatments for these conditions do not exist. Recent studies in Munc18‐1 (STXBP1) C. elegans models demonstrate that 4‐phenylbutyrate (4‐PBA) or related pharmacological chaperones stabilize ...
Aline Frick, Paige Whyte‐Fagundes, Scott C. Baraban   +2 more
wiley   +1 more source

Investigation of risk factors for autism spectrum disorder in children with tuberous sclerosis complex. [PDF]

BMC Psychiatry
Hu J, Zhao C, Fang Y, Zhang H, Liao J.
europepmc   +1 more source

NEAT1 Promotes Epileptogenesis in Tuberous Sclerosis Complex. [PDF]

Adv Sci (Weinh)
Kuang S, Liu T, Wei Z, Xu J, Han J, Wang J, Zhai F, Tian Y, Liang S.   +8 more
europepmc   +1 more source

ENT1 inhibitor J4 restores cognitive function and white-matter integrity in a mouse model of tuberous sclerosis complex. [PDF]

J Biomed Sci
Hsieh CC, Tsou YS, Huang NK, Chen TC, Li SJ, Chang CW, Lin WX, Tung SY, Chern Y, Chen YY, Lee YC.   +10 more
europepmc   +1 more source